AlgoTx

AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of Chemotherapy-Induced Peripheral Neuropathy, a common and painful side-effect of cancer treatments. It targets the signaling pathways involved in the regulation of pain by selectively inhibiting specific nociceptive sodium channel receptors. FDA granted ATX01 Fast-Track designation. The ACT study is an international Phase II randomized, placebo-controlled trial involving over 270 patients ; The results will be available in early 2025 and the company is making plans to expedite a Phase 3 trial. The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board. AlgoTx raised a Series B round of EUR 20 million in 2023 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, who led the Series B fund raise, along with UI Investissement, and angel investors. Historical investors include Bpifrance through its Innobio 2 fund and Omnes Capital. In 2023, the company won France Biotech’s prestigious ESG HealthTech Trophy in recognition of its early commitment to ESG initiatives. For more information, see the company’s website